If You're Struggling to Find Reyvow, You're Not Alone

If you've been to your pharmacy recently and heard the dreaded words "we don't have that in stock," you're not imagining things. Reyvow (Lasmiditan) is becoming increasingly difficult to find across the United States in 2026 — and the reason goes beyond a typical drug shortage.

In this article, we'll explain exactly what's happening with Reyvow, why it's disappearing from pharmacy shelves, and what steps you can take right now to manage your migraine treatment.

What Is Reyvow?

Reyvow is the brand name for Lasmiditan, a prescription medication approved by the FDA in October 2019 for the acute treatment of migraine with or without aura in adults. It was the first and only drug in a new class called ditans — specifically, a serotonin 5-HT1F receptor agonist.

Unlike triptans (such as Sumatriptan), Reyvow works by inhibiting neuronal firing without causing vasoconstriction. This made it an important option for migraine patients who couldn't safely take triptans due to cardiovascular conditions.

Reyvow is a Schedule V controlled substance and comes in 50 mg and 100 mg tablets. It's manufactured by Eli Lilly and Company. For more details about the drug itself, see our guide on what Reyvow is, its uses, and dosage.

Why Is Reyvow So Hard to Find in 2026?

Here's the key fact: Eli Lilly has permanently discontinued the manufacturing of Reyvow. This is not a temporary shortage. It's a permanent decision.

The Discontinuation Timeline

In November 2025, the FDA's Drug Shortages tracker listed Reyvow as "to be discontinued." Eli Lilly confirmed that they had made a voluntary business decision to stop manufacturing Reyvow globally. According to the company:

• The decision was not related to safety, efficacy, or quality concerns
• U.S. distribution of both the 50 mg and 100 mg tablets is expected to end on May 31, 2026
• Remaining supply will continue to be available until that date, depending on local pharmacy inventory

Why Lilly Discontinued Reyvow

Eli Lilly described this as a business decision. While they haven't provided detailed financial reasoning publicly, several factors likely contributed:

• Competition from gepants: Newer CGRP-targeting medications like Ubrelvy (Ubrogepant), Nurtec ODT (Rimegepant), and Zavzpret (Zavegepant) gained significant market share
• Controlled substance classification: Reyvow's Schedule V status created prescribing friction and additional regulatory requirements
• Driving restriction: Patients cannot drive for at least 8 hours after taking Reyvow, which limited its practical appeal

No Generic Alternative

To make matters worse, there is no generic version of Lasmiditan available. When a brand-name drug is discontinued and no generic exists, patients are left with no direct replacement. There's no other ditan on the market.

What Does This Mean for Patients?

If Reyvow is part of your migraine treatment plan, this discontinuation has real consequences:

• Existing prescriptions may go unfilled as pharmacies run out of stock
• Supply will become more spotty as the May 31, 2026 cutoff approaches
• You'll eventually need to switch to a different acute migraine medication
• The Reyvow Savings Card and Lilly Cares patient assistance program may also wind down

What You Can Do Right Now

Don't wait until the last minute. Here are practical steps you can take today:

1. Talk to Your Doctor About Alternatives

Your neurologist or prescriber should be aware of the discontinuation. Ask about switching to another acute migraine treatment. Options include:

• Ubrelvy (Ubrogepant) — an oral CGRP receptor antagonist, not a controlled substance
• Nurtec ODT (Rimegepant) — can be used for both acute treatment and prevention
• Zavzpret (Zavegepant) — a nasal spray gepant with fast onset
• Sumatriptan — a generic triptan that's very affordable, though not suitable for patients with cardiovascular disease

For a full comparison, read our post on alternatives to Reyvow.

2. Try to Fill Your Current Prescription Now

If you still have a valid Reyvow prescription, fill it as soon as possible while supply remains. Pharmacies with existing inventory can still dispense it.

3. Use Medfinder to Check Stock

Use Medfinder to search for pharmacies near you that may still have Reyvow in stock. Our tool helps you find availability in real time, so you don't have to call pharmacy after pharmacy. For more tips, see how to find Reyvow in stock near you.

4. Consider Independent Pharmacies

Large chain pharmacies often run out of stock first. Independent and specialty pharmacies may still carry Reyvow and can sometimes order it while distribution continues. Check our guide on how to check if a pharmacy has Reyvow in stock.

Final Thoughts

The discontinuation of Reyvow is disappointing news for the migraine community. As the only ditan on the market, it offered a unique mechanism of action that many patients relied on — especially those who couldn't take triptans.

But there are other effective options available. The most important thing you can do right now is have a conversation with your doctor about a transition plan. And if you need to fill your current prescription in the meantime, Medfinder can help you find a pharmacy with stock.

For the latest information, check our Reyvow shortage update for 2026.